中国现代医生2026，Vol.64Issue(7)：16-20,5.DOI:10.3969/j.issn.1673-9701.2026.07.004
血清miR-1298-5p表达对晚期非小细胞肺癌患者免疫治疗效果及预后的评估价值
The value of serum miR-1298-5p expression in evaluating efficacy and prognosis of immunotherapy in patients with advanced non-small cell lung cancer
摘要
Abstract
Objective To investigate the value of serum microRNA-1298-5p(miR-1298-5p)expression in evaluating efficacy and prognosis of immunotherapy in patients with advanced non-small cell lung cancer(aNSCLC).Methods A total of 120 aNSCLC patients who received immunotherapy at Ganzhou People's Hospital from January 2022 to April 2024 were selected and included in aNSCLC group,and 35 healthy individuals who came to the hospital for physical examination during the same period were included in control group.The aNSCLC patients were divided into ineffective group and effective group based on their 3-month immunotherapy efficacy,and into death group and survival group based on their 1-year follow-up prognosis.Multivariate unconditional Logistic regression analysis was performed to analyze the relationship between serum miR-1298-5p expression and immunotherapy prognosis in aNSCLC patients.Receiver operating characteristic curve analysis was used to assess the predictive efficacy of serum miR-1298-5p expression for immunotherapy response and prognosis in aNSCLC patients.Results The expression of serum miR-1298-5p in aNSCLC group was significantly lower than that in control group(P<0.05).Among 120 aNSCLC patients,immunotherapy inefficacy rate was 40.83%(49/120),and 1-year mortality rate was 62.50%(75/120).The expression of serum miR-1298-5p in ineffective group was significantly lower than that in effective group(P<0.05).The expression of serum miR-1298-5p in death group was significantly lower than that in survival group(P<0.05).The results of multivariate unconditional Logistic regression analysis showed that programmed death-ligand 1 combined positive score<5 was an independent risk factor for death after immunotherapy in aNSCLC patients,and high expression of serum miR-1298-5p was an independent protective factor(P<0.05).The area under the curve for serum miR-1298-5p expression in predicting immunotherapy inefficacy and death in aNSCLC patients was 0.796 and 0.816,with sensitivity of 91.84%and 64.00%,and specificity of 52.11%and 84.44%,respectively.Conclusion Serum miR-1298-5p expression is low in aNSCLC patients and is closely associated with inefficacy and death after immunotherapy.It may serve as an auxiliary indicator for assessing the efficacy and prognosis of immunotherapy in aNSCLC patients.关键词
非小细胞肺癌/晚期/微RNA-1298-5p/免疫治疗/治疗效果/预后Key words
Non-small cell lung cancer/Advanced/MicroRNA-1298-5p/Immunotherapy/Treatment efficacy/Prognosis分类
医药卫生引用本文复制引用
邓尘飞扬,陈雪娇,赖旭旺,赖景春..血清miR-1298-5p表达对晚期非小细胞肺癌患者免疫治疗效果及预后的评估价值[J].中国现代医生,2026,64(7):16-20,5.基金项目
江西省赣州市重点研发计划项目(GZ2024YLJ046) （GZ2024YLJ046）
